Investing.com - Intracellular Th (NASDAQ: ITCI) reported third quarter EPS of $-0.25, $0.07 worse than the analyst estimate of $-0.18. Revenue for the quarter came in at $175.4M versus the consensus estimate of $172.35M.
Guidance
Intracellular Th sees Q4 2024 revenue of $665.00M-$685.00M versus the analyst consensus of $666.60M.
Intracellular Th's stock price closed at $76.75. It is down -0.71% in the last 3 months and up 54.24% in the last 12 months.
Intracellular Th saw 2 positive EPS revisions and 10 negative EPS revisions in the last 90 days. See Intracellular Th's stock price’s past reactions to earnings here.
According to InvestingPro, Intracellular Th's Financial Health score is "great performance".
Check out Intracellular Th's recent earnings performance, and Intracellular Th's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar